Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, announced a virtual Key Opinion Leader $(KOL)$ event scheduled for June 24, 2025, at 3:30PM EST. The event will focus on HT-001, a novel topical therapeutic developed to address skin toxicities induced by EGFR inhibitors in cancer patients. The presentation will include interim results from an ongoing Phase 2 trial, with insights from specialists in derm-oncology and dermatology, Jonathan Hale Zippin M.D., Ph.D., and Adam Friedman M.D., F.A.A.D. This event will highlight the recent clinical progress of HT-001 and its potential to redefine supportive care standards for oncology patients. The event can be accessed through the provided Zoom link.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.